pharma · Advanced Solid Tumor · Sarcoma · PRLD
Prelude Therapeutics
Prelude Therapeutics Inc
Prelude Therapeutics is a pharma organization headquartered in Wilmington, USA. It trades on NYSE under ticker PRLD. Primary therapeutic focus areas include Advanced Solid Tumor, Sarcoma, Acute Myeloid Leukemia, Polycyth
175 Innovation Boulevard, Wilmington, DE 19805, US HQ
2016 Founded
111 Employees
Public company Type
PRLD · NYSE Ticker
Company details
- Status
- Public
- HQ
- 175 Innovation Boulevard, Wilmington, DE 19805, US
- Founded
- 2016
- Employees
- 111
- Programs
- 13
- Drugs
- 5
- Patents
- 16
PRT2527
Phase 1 · small molecule · Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)
PRT2527 for Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL) is a Phase 1 program (small_molecule) at Prelude Therapeutics Inc with 1 ClinicalTrials.gov record(s).
Internal code PRT2527-02
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Prelude Therapeutics Inc
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)
- Status
- completed
- Trials
- 1